News

TORONTO (March 10, 2022) – Cystic Fibrosis Canada today announces that it has achieved reaccreditation under Imagine Canada’s Standards Program, being an accredited member of the Standard Program since October 1^st, 2015. Accredited organizations are required to complete full reaccreditation on a five-year basis. With this achievement, Cystic Fibrosis Canada remains a distinguished member of the ever-growing community of 250+ nonprofit organizations dedicated to operational excellence.   

TORONTO 4 March, 2022 - The Quebec Court of Appeal has issued a much-anticipated decision in the court case brought forward by a number of pharmaceutical companies, led by Merck Canada, Inc, and on which Cystic Fibrosis Canada intervened. In a unanimous decision the three judges struck down two key proposed changes to the Patented Medicine Prices Review Board (PMPRB) guidelines, opening the way to improved access to medicines for patients living with cystic fibrosis.

New CF Trends Report finds a disease in transition 

Cystic Fibrosis Canada launches sixth annual holiday campaign to lengthen and improve lives

Funding approval not leading to access across country that is deserved and needed 

All provinces and nearly every territory now offers public funding of this life changing drug. 

Cystic Fibrosis Canada calls on remaining jurisdictions to fund the cystic fibrosis drug today

CF Canada calls on the Northwest Territories, Nunavut and Federal Drug Programs to Fund Trikafta